论文部分内容阅读
本文采用蛇毒抗栓酶三号(Svate-3)治疗冠心病心室晚电位(VLP)阳性患者27例.其中男24例、女3例.平均61.1岁。冠心病诊断全部符合WHO诊断标准.27例经WLP-2800型晚电位仪检测,诊断为VLP阳性.阳性标准采用泸波范围25-250Hz,①RMS-40<25μv,②LAS≥34ms,③TQRS≥120ms.三项中①异常加上②、③两项中任一项异常诊为VLP阳性.27例治疗采用大连司威特制药有限公司生产的Svate-3.0.75~u加入0.9％生理盐水250ml中静脉点滴,每日1次,21次为1疗程。27例经1疗程治疗原VLP指标全部由阳性转阴性.RMS-40、LAS、TQRS三项治疗前分别为:13.95±5.69μv、47.74±11.04ms、114.00±22.60ms治疗后为73.70±48.08μv、27.60±
In this paper, 27 cases of positive ventricular (VLP) positive patients with coronary heart disease were treated with Svate-3, including 24 males and 3 females with an average age of 61.1 years. The diagnosis of coronary heart disease all met the WHO diagnostic criteria .27 cases were detected by WLP-2800 late potentiometer, the diagnosis of VLP positive.The positive standard using the range of 25-250Hz in the wave, ①RMS-40 <25μv, ②LAS≥34ms, ③TQRS≥120ms. Three abnormalities plus ②, ③ two of either abnormal diagnosis of VLP-positive .27 cases of treatment with Dalian Siweite Pharmaceutical Co., Ltd. produced Svate-3.0.75 ~ u added 0.9% saline 250ml medium vein Drip, 1 day, 21 times for a course of treatment. 27 cases treated by a course of treatment of the original VLP index negative by the positive.RMS-40, LAS, TQRS three before treatment were: 13.95 ± 5.69μv, 47.74 ± 11.04ms, 114.00 ± 22.60ms after treatment was 73.70 ± 48.08μv , 27.60 ±